Scientists collect prostate samples to unlock cancer secrets
NCT ID NCT00578240
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study collects tissue, blood, and other fluid samples from men with prostate conditions, including those with no cancer, localized disease, or advanced stages. Researchers will analyze genetic changes and protein markers to understand why some men get prostate cancer, why some cancers are more aggressive, and why some respond or resist treatment. The goal is to improve diagnosis, prevention, and treatment of prostate cancer.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this research could help scientists find better ways to diagnose, prevent, and treat prostate cancer.
- What could go wrong
- This is an observational study collecting samples for future research, not testing a new treatment. It may not directly lead to new therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
5,290 people
The number who actually took part.
- Start date
-
Apr 1990
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
All patients meeting the eligibility criteria and receiving or seeking prostate cancer treatment in the Genitourinary Oncology/Urology Services will be approached by a consenting professional at a suitable point in their clinical course prior to biospecimen collection.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Men with prostate conditions representing the following disease states: * No Cancer Diagnosis * Clinically Localized Disease * Rising PSA * Clinical Metastases: Noncastrate * Clinical Metastases: Castrate (Testosterone ≤ 50 ng/ml) * Signed informed consent Exclusion Criteria: -Patients without any prostate related problems.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Prostate cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Radioactive missile aims at prostate cancer that spread
- New PET tracer targets ACP3 to spot prostate cancer
- Can a One-Week radiation course match four weeks for prostate cancer?
- Can a new PET tracer spot hidden prostate cancer spread?
- Can a gel cushion shield the rectum during prostate radiation?
- A scanner in the operating room could show surgeons exactly where prostate cancer remains